vs
Krispy Kreme, Inc.（DNUT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Krispy Kreme, Inc.的1.6倍（$622.0M vs $392.4M），Royalty Pharma plc净利率更高（34.4% vs -7.1%，领先41.5%），Royalty Pharma plc同比增速更快（4.8% vs -2.9%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -5.9%）
Krispy Kreme是源自美国的跨国甜甜圈烘焙与咖啡连锁品牌，1937年由弗农·鲁道夫在美国北卡罗来纳州温斯顿-塞勒姆创立。品牌创始时采用鲁道夫从新奥尔良厨师手中购得的酵母甜甜秘方配方开店，历经数十年稳步发展，如今已成为全球知名的甜甜圈休闲餐饮连锁品牌。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DNUT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$392.4M
营收增速更快
RPRX
高出7.7%
-2.9%
净利率更高
RPRX
高出41.5%
-7.1%
两年增速更快
RPRX
近两年复合增速
-5.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $392.4M | $622.0M |
| 净利润 | $-27.8M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | -1.9% | 62.4% |
| 净利率 | -7.1% | 34.4% |
| 营收同比 | -2.9% | 4.8% |
| 净利润同比 | -23.8% | 2.9% |
| 每股收益（稀释后） | $-0.18 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNUTRPRX
| Q4 25 | $392.4M | $622.0M | ||
| Q3 25 | $375.3M | $609.3M | ||
| Q2 25 | $379.8M | $578.7M | ||
| Q1 25 | $375.2M | $568.2M | ||
| Q4 24 | $404.0M | $593.6M | ||
| Q3 24 | $379.9M | $564.7M | ||
| Q2 24 | $438.8M | $537.3M | ||
| Q1 24 | $442.7M | $568.0M |
净利润DNUTRPRX
| Q4 25 | $-27.8M | $214.2M | ||
| Q3 25 | $-19.4M | $288.2M | ||
| Q2 25 | $-435.3M | $30.2M | ||
| Q1 25 | $-33.3M | $238.3M | ||
| Q4 24 | $-22.4M | $208.2M | ||
| Q3 24 | $39.6M | $544.0M | ||
| Q2 24 | $-5.5M | $102.0M | ||
| Q1 24 | $-8.5M | $4.8M |
营业利润率DNUTRPRX
| Q4 25 | -1.9% | 62.4% | ||
| Q3 25 | -1.9% | 70.1% | ||
| Q2 25 | -114.4% | 36.3% | ||
| Q1 25 | -5.4% | 94.0% | ||
| Q4 24 | -2.8% | 60.9% | ||
| Q3 24 | -4.2% | — | ||
| Q2 24 | 1.6% | 50.2% | ||
| Q1 24 | 2.7% | -13.0% |
净利率DNUTRPRX
| Q4 25 | -7.1% | 34.4% | ||
| Q3 25 | -5.2% | 47.3% | ||
| Q2 25 | -114.6% | 5.2% | ||
| Q1 25 | -8.9% | 41.9% | ||
| Q4 24 | -5.6% | 35.1% | ||
| Q3 24 | 10.4% | 96.3% | ||
| Q2 24 | -1.3% | 19.0% | ||
| Q1 24 | -1.9% | 0.8% |
每股收益（稀释后）DNUTRPRX
| Q4 25 | $-0.18 | $0.49 | ||
| Q3 25 | $-0.11 | $0.67 | ||
| Q2 25 | $-2.55 | $0.07 | ||
| Q1 25 | $-0.20 | $0.55 | ||
| Q4 24 | $-0.13 | $0.46 | ||
| Q3 24 | $0.23 | $1.21 | ||
| Q2 24 | $-0.03 | $0.23 | ||
| Q1 24 | $-0.05 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.4M | $618.7M |
| 总债务越低越好 | $911.9M | $9.0B |
| 股东权益账面价值 | $650.1M | $9.7B |
| 总资产 | $2.6B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.40× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DNUTRPRX
| Q4 25 | $42.4M | $618.7M | ||
| Q3 25 | $30.7M | $938.9M | ||
| Q2 25 | $21.3M | $631.9M | ||
| Q1 25 | $18.7M | $1.1B | ||
| Q4 24 | $29.0M | $929.0M | ||
| Q3 24 | $25.4M | $950.1M | ||
| Q2 24 | $28.6M | $1.8B | ||
| Q1 24 | $33.1M | $843.0M |
总债务DNUTRPRX
| Q4 25 | $911.9M | $9.0B | ||
| Q3 25 | $906.2M | $8.9B | ||
| Q2 25 | $889.4M | $8.0B | ||
| Q1 25 | $935.0M | $7.6B | ||
| Q4 24 | $844.5M | $7.6B | ||
| Q3 24 | $804.6M | $7.6B | ||
| Q2 24 | $895.0M | $7.6B | ||
| Q1 24 | $881.8M | $6.1B |
股东权益DNUTRPRX
| Q4 25 | $650.1M | $9.7B | ||
| Q3 25 | $670.3M | $9.6B | ||
| Q2 25 | $693.6M | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.2B | $10.3B | ||
| Q2 24 | $1.1B | $9.8B | ||
| Q1 24 | $1.2B | $9.9B |
总资产DNUTRPRX
| Q4 25 | $2.6B | $19.6B | ||
| Q3 25 | $2.6B | $19.3B | ||
| Q2 25 | $2.6B | $18.3B | ||
| Q1 25 | $3.1B | $17.6B | ||
| Q4 24 | $3.1B | $18.2B | ||
| Q3 24 | $3.1B | $18.0B | ||
| Q2 24 | $3.2B | $17.7B | ||
| Q1 24 | $3.2B | $16.1B |
负债/权益比DNUTRPRX
| Q4 25 | 1.40× | 0.92× | ||
| Q3 25 | 1.35× | 0.93× | ||
| Q2 25 | 1.28× | 0.84× | ||
| Q1 25 | 0.85× | 0.78× | ||
| Q4 24 | 0.74× | 0.74× | ||
| Q3 24 | 0.68× | 0.74× | ||
| Q2 24 | 0.79× | 0.78× | ||
| Q1 24 | 0.76× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $27.9M | — |
| 自由现金流率自由现金流/营收 | 7.1% | — |
| 资本支出强度资本支出/营收 | 4.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-64.0M | — |
8季度趋势，按日历期对齐
经营现金流DNUTRPRX
| Q4 25 | $45.0M | $827.1M | ||
| Q3 25 | $42.3M | $702.6M | ||
| Q2 25 | $-32.5M | $364.0M | ||
| Q1 25 | $-20.8M | $596.1M | ||
| Q4 24 | $27.0M | $742.5M | ||
| Q3 24 | $3.3M | $703.6M | ||
| Q2 24 | $33.2M | $658.2M | ||
| Q1 24 | $-17.7M | $664.6M |
自由现金流DNUTRPRX
| Q4 25 | $27.9M | — | ||
| Q3 25 | $15.5M | — | ||
| Q2 25 | $-60.8M | — | ||
| Q1 25 | $-46.7M | — | ||
| Q4 24 | $-6.9M | — | ||
| Q3 24 | $-22.9M | — | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $-46.8M | — |
自由现金流率DNUTRPRX
| Q4 25 | 7.1% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | -16.0% | — | ||
| Q1 25 | -12.5% | — | ||
| Q4 24 | -1.7% | — | ||
| Q3 24 | -6.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | -10.6% | — |
资本支出强度DNUTRPRX
| Q4 25 | 4.4% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 6.9% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 7.2% | — | ||
| Q1 24 | 6.6% | — |
现金转化率DNUTRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 0.08× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNUT
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
